Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Congenital Hepatic Fibrosis Clear all

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • St. Petersburg, Florida

Conditions: CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions: Fibroscan; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Abdominal Ultrasound, Sample collection procedures; Procedure · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 10
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more

Conditions: Liver Cirrhosis, Hemophilia, Hemophilia A, Hemophilia B, Liver Transplant Disorder, Liver Failure, Coagulation Factor Deficiency
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Sickle Cell Disease
Interventions: Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.; Other · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 10 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ciliopathy
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 5 Months to 80 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease, Pancreatic Steatosis, Hepatic Steatosis
Interventions: Frequently Sampled Oral Glucose Tolerance Test and CGM, MRI Pancreas and Liver; Device · Radiation
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2030
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions: Cannabidiol; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more

Conditions: Cystic Fibrosis Liver Disease
Interventions: Transient Elastography (TE); Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 26 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions: Liver Stiffness Measurement (LSM); Other
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 21 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions: Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron; Device · Procedure · Other + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Natural History of Noncirrhotic Portal Hypertension

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

Liver Disease in Urea Cycle Disorders

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

Liver Fibrosis in Sickle Cell Disease

Clinical and Molecular Investigations Into Ciliopathies

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

ARPKD Database Study

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Longitudinal Assessment of Transient Elastography in Cystic Fibrosis

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)